Rigshospitalet

Running trials

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Source

• Not yet recruiting

  Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI

  NCT07861217· Phase 2· Source

• Not yet recruiting

  Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer

  NCT07903883· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Source

• Recruiting

  FLuorescent Assisted Surgery for Head and neck cancer: Perioperative Optical Imaging in Neck dissection and Transoral robotic surgery (FLASHPOINT)

  2025-522845-23-00· Phase 2· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Source

• Not yet recruiting

  PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors

  NCT07590726· Source

• Recruiting

  A dosimetry trial of uPAR targeted radioligand therapy in patients with glioblastoma

  2024-520105-39-00· Phase 1· Source

• Not yet recruiting

  Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform

  NCT07825233· Source

• Recruiting

  A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors

  2025-523665-24-00· Phase 1· Source

• Not yet recruiting

  Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE

  NCT07870681· Phase 2/3· Source

• Not yet recruiting

  bNAbs and Anti-PD-1 in HIV

  NCT07820813· Phase 2· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Source

• Not yet recruiting

  A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

  2025-524314-29-00· Phase 3· Source

• Enrolling by invitation

  Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients

  NCT07886489· Source

• Recruiting

  Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer

  NCT07432802· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Not yet recruiting

  A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)

  2025-524439-38-00· Phase 2· Source

• Not yet recruiting

  RECAP-D

  2026-526685-25-00· Phase 2· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Not yet recruiting

  The HYCORE1 Trial: Hybrid Revascularization Versus Coronary Artery Bypass Grafting

  NCT05504031· Source

• Recruiting

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Phase 1· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  NCT07630974· Phase 1/2· Source

• Recruiting

  A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

  NCT07647510· Phase 3· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Source

• Recruiting

  Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

  2024-516896-34-00· Phase 1/2· Source

• Active, not recruiting

  Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

  NCT07468071· Phase 1/2· Source

• Not yet recruiting

  A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

  NCT07455422· Source

• Not yet recruiting

  UNPRESCRIB-D

  2026-526314-90-00· Phase 4· Source

• Not yet recruiting

  The MAYA2 trial

  2025-521941-25-00· Phase 2· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Source

• Recruiting

  Vascular Complications After Kidney Transplantation

  NCT07531966· Source

• Recruiting

  A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors

  2025-521702-18-00· Phase 1· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

  NCT07416526· Phase 3· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Source

• Recruiting

  Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial

  NCT07478003· Phase 3· Source

• Recruiting

  Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

  NCT07481175· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers63 recruiting
• Lung cancer19 recruiting
• Colorectal cancer16 recruiting
• Heart failure16 recruiting
• Acute myeloid leukemia15 recruiting
• Acute lymphoblastic leukaemia13 recruiting
• Atrial fibrillation12 recruiting
• Coronary artery disease12 recruiting
• Stroke12 recruiting
• Myelodysplastic syndromes9 recruiting
• Ovarian cancer9 recruiting
• Prostate cancer9 recruiting
• Sarcoma9 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)8 recruiting
• Chronic kidney disease7 recruiting
• Bladder cancer6 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Head and neck cancer6 recruiting
• High blood pressure6 recruiting
• Hodgkin lymphoma6 recruiting
• Metastatic breast cancer6 recruiting
• Neuroblastoma6 recruiting
• Obesity6 recruiting
• Type 2 diabetes6 recruiting
• Melanoma5 recruiting
• Pancreatic cancer5 recruiting
• Amyloidosis4 recruiting
• Chronic myeloid leukaemia4 recruiting
• Crohn's disease4 recruiting
• Endometrial cancer4 recruiting
• Follicular lymphoma4 recruiting
• Haemophilia4 recruiting
• Mantle cell lymphoma4 recruiting
• Multiple myeloma4 recruiting
• Myasthenia gravis4 recruiting
• Type 1 diabetes4 recruiting
• Cystic fibrosis3 recruiting
• Gastric and esophageal cancer3 recruiting
• Glioblastoma3 recruiting
• HIV3 recruiting
• Lupus (SLE)3 recruiting
• ANCA-associated vasculitis2 recruiting
• Cervical cancer2 recruiting
• Depression2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Fabry disease2 recruiting
• Hepatitis B2 recruiting
• Huntington's disease2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Liver and biliary tract cancer2 recruiting
• Macular degeneration2 recruiting
• Multiple sclerosis2 recruiting
• Neuroendocrine tumours2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Rheumatoid arthritis2 recruiting
• Sjögren's disease2 recruiting
• Thalassaemia2 recruiting
• Alzheimer disease1 recruiting
• Autism1 recruiting
• COPD1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epilepsy1 recruiting
• Glaucoma1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Osteoporosis1 recruiting
• Pompe disease1 recruiting
• Sickle cell disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment

  2025-523307-29-00· Phase 3· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· Source

• Not yet recruiting

  A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

  2024-515627-10-00· Phase 1/2· Source

• Completed

  ARIISE - ASCs in recently diagnosed non-ischemic heart failure

  NCT06840275· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Source

• Completed

  Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP)

  NCT04054830· Phase 4· Source

• Active, not recruiting

  Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)

  2025-521681-10-00· Phase 2· Source

• Recruiting

  Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)

  2024-520050-38-00· Phase 3· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Source

• Completed

  A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP

  2024-518364-12-00· Phase 2· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· Source

• Active, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567· Phase 1/2· Source

• Completed

  Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors

  NCT06232408· Phase 1· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· Phase 1· Source

• Recruiting

  Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

  NCT06613009· Phase 1· Source

• Completed

  ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

  2024-514111-10-00· Phase 4· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· Phase 2· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· Source

• Active, not recruiting

  A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

  NCT06413706· Phase 2· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Source

• Completed

  Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour

  NCT06796335· Source

• Completed

  A safety study of PF-08046044/SGN-35C in adults with advanced cancers

  NCT06254495· Phase 1· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Source

• Completed

  A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)

  2023-506240-16-00· Phase 1/2· Source

• Completed

  Mobilization Before and After Video-Assisted Thoracoscopic Surgery Lobectomy/Segmentectomy

  NCT07338474· Source

• Active, not recruiting

  Iptacopan in Patients With ANCA Associated Vasculitis

  NCT06388941· Phase 2· Source

• Completed

  Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

  NCT06435273· Phase 2· Source

• Active, not recruiting

  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  NCT06456580· Phase 3· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

  NCT06483334· Phase 1/2· Source

• Completed

  A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)

  NCT06465303· Phase 2· Source

• Completed

  Pulmonary Diffusing Capacity During Incremental Exercise in COPD

  NCT06505902· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Completed

  A safety study of PF-08046045/SGN-35T in adults with advanced cancers

  NCT06120504· Phase 1· Source

• Completed

  Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)

  NCT06287476· Source

• Completed

  Strength Training Exercises to Minimise Late Effects of Childhood Leukaemia or Lymphoma Among Adolescents

  NCT06299722· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· Source

• Completed

  Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia

  NCT07062250· Source

• Active, not recruiting

  A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)

  2023-506183-13-00· Phase 2· Source

• Completed

  A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  2022-502457-34-00· Phase 2· Source

• Completed

  A Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with SBMA

  2023-507128-22-00· Phase 2· Source

• Completed

  GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

  2022-502453-33-00· Phase 2· Source

• Recruiting

  An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

  NCT06035120· Source

• Recruiting

  A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

  NCT06234423· Phase 1· Source

• Completed

  Maximal Oxygen Uptake (VO2max) in Patients With COPD

  NCT06257381· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Source

• Completed

  A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma

  NCT06018129· Phase 1/2· Source

Trial sites

• #4001, Rigshospitalet - Blegdamsvej0 trials
• Børneonkologisk afsnit 5054, BørneUngeKlinikken, Juliane Marie Centret, Rigshospitalet0 trials
• Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark.3 trials
• Center for Cancer and Organ Diseases - Rigshospitalet2 trials
• Center for Cancer and Organ Diseases - Rigshospitalet - Hornum Mads0 trials
• Center For Physical Activity Research, Rigshospitalet1 trial
• Center for Pregnant Women with Diabetes, Rigshospitalet1 trial
• Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet1 trial
• Copenhagen Neuromuscular Center, Rigshospitalet1 trial
• Department for Cardiothoracic Surgery, Rigshospitalet1 trial
• Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen4 trials
• Department of Cardiology, Rigshospitalet3 trials
• Department of Clinical Oncology, Rigshospitalet1 trial
• Department of Endocrinology, Rigshospitalet1 trial
• Department of Growth and Reproduction, Rigshospitalet2 trials
• Department of Hematology, Rigshospitalet0 trials
• Department of Nephrology, Rigshospitalet2 trials
• Department of neurosurgery, Rigshospitalet1 trial
• Department of Obstetrics, Rigshospitalet1 trial
• Department of Oncology 5073, Rigshospitalet1 trial
• Department of Oncology, Rigshospitalet1 trial
• Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet1 trial
• Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet1 trial
• Department of Pediatrics and Adolescent Medicine and Copenhagen Neuromuscular Center, Rigshospitalet1 trial
• Department of Urology, Rigshospitalet1 trial
• Dep. of Hematology, Rigshospitalet0 trials
• Dept. of Nephrology, Rigshospitalet1 trial
• Dept. of Oncology, Rigshospitalet, Denmark1 trial
• Dept. of Otorhinolaryngology, Head & Neck Surg, Rigshospitalet1 trial
• Heart Center, Rigshospitalet2 trials
• Hjertecenteret, Rigshospitalet1 trial
• Juliane Marie Center, Rigshospitalet1 trial
• Kardiologisk Forskningsenhed 2161, Rigshospitalet1 trial
• Medical Endocrinology PE 2132, Rigshospitalet0 trials
• Neurobiology Research Unit, Rigshospitalet1 trial
• Paediatric Stem Cell Transplant and Immune Deficiency, Dept. for children and adolescents 4072, Rigshospitalet0 trials
• Rigshospitalet165 trials
• Rigshospitalet - Børn og Unge0 trials
• Rigshospitalet (CFAS)2 trials
• Rigshospitalet, Copenhagen12 trials
• Rigshospitalet, Copenhagen Prostate Cancer Center1 trial
• Rigshospitalet, Department of Cardiology0 trials
• Rigshospitalet, Department of Clinical Biochemistry and Endocrinology1 trial
• Rigshospitalet, Department of Hematology1 trial
• Rigshospitalet, Department of Otorhinolaryngology, Head and Neck Surgery & Audiology1 trial
• Rigshospitalet, Department of Otorhinolaryngology, Head & Neck Surgery & Audiology2 trials
• Rigshospitalet, Dept of Haematology1 trial
• Rigshospitalet, Dept of Paediatrics1 trial
• Rigshospitalet, Dept of Radiology0 trials
• Rigshospitalet - Glostrup0 trials
• Rigshospitalet, Hjertecentret1 trial
• Rigshospitalet - Juliane Marie Centret (JMC) Copenhagen1 trial
• Rigshospitalet - Neurologisk Afdeling0 trials
• Rigshospitalet, Region h, Department Oncology1 trial
• Rigshospitalet (RH)1 trial
• Rigshospitalet (Site 0199)1 trial
• Rigshospitalet (Site 0304)1 trial
• Rigshospitalet (Site 0576)0 trials
• Rigshospitalet (Site 0680)1 trial
• Rigshospitalet (Site 0702)1 trial
• Rigshospitalet (Site 0801)0 trials
• Rigshospitalet (Site 0802)0 trials
• Rigshospitalet (Site 0903)0 trials
• Rigshospitalet (Site 0904)0 trials
• Rigshospitalet (Site 1102)0 trials
• Rigshospitalet (Site 1180)1 trial
• Rigshospitalet (Site 1904)0 trials
• Rigshospitalet (Site 2102)1 trial
• Rigshospitalet (Site 3202)1 trial
• Rigshospitalet (Site 4467)0 trials
• The Heart Center, Rigshospitalet1 trial
• The Heart Center, Rigshospitalet, University of Copenhagen1 trial
• The Heart Centre, Rigshospitalet1 trial
• Urological Research Unit, Rigshospitalet1 trial
• Rigshospitalet0 trials
• Rigshospitalet0 trials
• Rigshospitalet (Blegdamsvej)1 trial
• Rigshospitalet /ID# 1248911 trial
• Rigshospitalet /ID# 1644200 trials
• Rigshospitalet /ID# 2242130 trials
• Rigshospitalet /ID# 2265760 trials
• Rigshospitalet /ID# 2607790 trials
• Rigshospitalet /ID# 982381 trial
• Rigshospitalet402 trials
• Rigshospitalet - Kræftbehandling1 trial
• Rigshospitalet40 trials
• Rigshospitalet1 trial
• Rigshospitalet0 trials
• Rigshospitalet1 trial
• Rigshospitalet19 trials
• Rigshospitalet1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure485 works · 29 trials
• Stroke371 works · 23 trials
• Atrial fibrillation214 works · 21 trials
• Type 2 diabetes156 works · 8 trials
• Migraine145 works · 10 trials
• Chronic kidney disease136 works · 19 trials
• Coronary artery disease123 works · 30 trials
• Multiple sclerosis109 works · 15 trials
• Rheumatoid arthritis98 works · 4 trials
• Ovarian cancer85 works · 19 trials
• Epilepsy77 works · 1 trials
• COPD58 works · 8 trials
• Multiple myeloma55 works · 24 trials
• Depression44 works · 3 trials
• Sarcoma43 works · 13 trials
• Osteoporosis41 works · 1 trials
• Cystic fibrosis29 works · 7 trials
• Acute lymphoblastic leukaemia28 works · 25 trials
• Ankylosing spondylitis26 works · 1 trials
• Type 1 diabetes23 works · 5 trials
• Childhood cancers22 works · 106 trials
• Lupus (SLE)21 works · 4 trials
• Head and neck cancer21 works · 15 trials
• Psoriatic arthritis20 works · 1 trials
• Myasthenia gravis20 works · 13 trials
• Hodgkin lymphoma20 works · 22 trials
• Endometrial cancer19 works · 11 trials
• Chronic lymphocytic leukaemia16 works · 21 trials
• Hypertrophic cardiomyopathy14 works · 2 trials
• Macular degeneration13 works · 5 trials